A Comparison of Reported Gastrointestinal and Thromboembolic Events Between Rofecoxib and Celecoxib Using Observational Data

This publication has 34 references indexed in Scilit:

• The Risk for Myocardial Infarction with Cyclooxygenase-2 Inhibitors: A Population Study of Elderly Adults
  Annals of Internal Medicine, 2005
• Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial
  New England Journal of Medicine, 2005
• Complications of the COX-2 Inhibitors Parecoxib and Valdecoxib after Cardiac Surgery
  New England Journal of Medicine, 2005
• Risk of Upper Gastrointestinal Hemorrhage in Warfarin Users Treated With Nonselective NSAIDs or COX-2 Inhibitors
  Archives of internal medicine (1960), 2005
• Incidence of Thrombotic Cardiovascular Events in Patients Taking Celecoxib Compared with Those Taking Rofecoxib
  Drug Safety, 2005
• Risk of cardiovascular events and rofecoxib: cumulative meta-analysis
  The Lancet, 2004
• Coxibs and Cardiovascular Disease
  New England Journal of Medicine, 2004
• Comparison of the incidence rates of selected gastrointestinal events reported for patients prescribed celecoxib and meloxicam in general practice in England using prescription-event monitoring (PEM) data
  Rheumatology, 2003
• Comparison of the incidence rates of selected gastrointestinal events reported for patients prescribed rofecoxib and meloxicam in general practice in England using prescription-event monitoring data
  Rheumatology, 2003
• Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2
  Proceedings of the National Academy of Sciences, 1999